Arcturus Therapeutics Ltd (ARCT) Stock Price, Quote & News

Company Profile

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 900 2660

Website: arcturusrx.com

Address:

10628 Science Center Drive, Suite 250, San Diego, United States

judgeyoung2 Oct. 8 at 6:04 PM

$ARCT okay the IV re elevated which makes me think they just wanted to grab options cheaply

0 · Reply

MaxCorona Oct. 8 at 6:04 PM

$ARCT had my finger already on the trigger to sell some. But in that moment this Beats recovered. So only a short attack.

0 · Reply

Choice79 Oct. 8 at 6:03 PM

$ARCT man the share price is all over the place.

0 · Reply

SeeKingProphets Oct. 8 at 5:34 PM

$ARCT they dropped the price and are absolutely loading the boat on calls. This is after they sold puts on the artificial drop last week that have decreased in value. This one could rip! 🚀

0 · Reply

wahoowa96 Oct. 8 at 4:38 PM

$ARCT Woodline LP are former Citadel chickens.

0 · Reply

shitfeed Oct. 8 at 4:37 PM

0 · Reply

redistributeW Oct. 8 at 4:18 PM

$ARCT Dumping???

0 · Reply

Nganlm Oct. 8 at 4:12 PM

$ARCT huge volumes in Oct options today especially calls, some in Nov as well. For Oct, not sure if closing open positions or new ones. For Nov, should be new as open positions is low.

1 · Reply

SeeKingProphets Oct. 8 at 4:07 PM

$ARCT more manipulation today from the market maker. Paper hands need to move on. IYKYK 🌋

0 · Reply

bigchouse Oct. 8 at 4:07 PM

$ARCT Here are the MMs that are shorting. Woodline Partners LP Schonfeld Strategic Advisors LLC Balyasny Asset Management LP

0 · Reply

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Aug 11, 2025, 8:16 PM EDT - 2 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript

Aug 11, 2025, 4:01 PM EDT - 2 months ago

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

Jul 24, 2025, 4:01 PM EDT - 2 months ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jun 30, 2025, 11:00 AM EDT - 3 months ago

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Jun 23, 2025, 8:30 AM EDT - 3 months ago

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

May 12, 2025, 7:40 PM EDT - 5 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 5 months ago

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

Apr 22, 2025, 4:01 PM EDT - 6 months ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Apr 10, 2025, 8:00 AM EDT - 6 months ago

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Mar 6, 2025, 9:44 PM EST - 7 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:01 PM EST - 7 months ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Mar 5, 2025, 4:30 PM EST - 7 months ago

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Feb 24, 2025, 4:01 PM EST - 8 months ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Feb 14, 2025, 8:30 AM EST - 8 months ago

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Feb 4, 2025, 8:30 AM EST - 8 months ago

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Jan 31, 2025, 3:00 AM EST - 8 months ago

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Jan 30, 2025, 4:01 PM EST - 8 months ago

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 10, 2025, 8:00 AM EST - 9 months ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Jan 6, 2025, 4:01 PM EST - 9 months ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Dec 16, 2024, 4:01 PM EST - 10 months ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 18, 2024, 8:00 PM EST - 11 months ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 1:44 PM EST - 11 months ago

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14, 2024, 1:00 AM EST - 11 months ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 11, 2024, 4:01 PM EST - 11 months ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 7, 2024, 11:24 PM EST - 11 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 11 months ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Sep 13, 2024, 8:15 AM EDT - 1 year ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Aug 27, 2024, 5:00 PM EDT - 1 year ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Aug 9, 2024, 5:27 AM EDT - 1 year ago

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 5, 2024, 8:50 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Jul 18, 2024, 7:30 PM EDT - 1 year ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Jul 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Jun 8, 2024, 2:42 AM EDT - 1 year ago

Arcturus: A Hidden Gem In The Biotech Sector

Jun 7, 2024, 10:30 AM EDT - 1 year ago

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

May 28, 2024, 6:30 AM EDT - 1 year ago

Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program

May 20, 2024, 8:30 AM EDT - 1 year ago

Nature Communications Publishes Pivotal Data Demonstrating Efficacy and Tolerability of CSL and Arcturus Therapeutics' COVID-19 Vaccine

May 8, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Apr 25, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024

Apr 23, 2024, 6:01 AM EDT - 1 year ago

Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis

Mar 7, 2024, 6:32 PM EST - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2023 Earnings Call Transcript

Mar 7, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress

Feb 26, 2024, 9:00 AM EST - 1 year ago

Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference

Feb 22, 2024, 8:30 AM EST - 1 year ago

Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis

judgeyoung2 Oct. 8 at 6:04 PM

$ARCT okay the IV re elevated which makes me think they just wanted to grab options cheaply

0 · Reply

MaxCorona Oct. 8 at 6:04 PM

$ARCT had my finger already on the trigger to sell some. But in that moment this Beats recovered. So only a short attack.

0 · Reply

Choice79 Oct. 8 at 6:03 PM

$ARCT man the share price is all over the place.

0 · Reply

SeeKingProphets Oct. 8 at 5:34 PM

$ARCT they dropped the price and are absolutely loading the boat on calls. This is after they sold puts on the artificial drop last week that have decreased in value. This one could rip! 🚀

0 · Reply

wahoowa96 Oct. 8 at 4:38 PM

$ARCT Woodline LP are former Citadel chickens.

0 · Reply

shitfeed Oct. 8 at 4:37 PM

0 · Reply

redistributeW Oct. 8 at 4:18 PM

$ARCT Dumping???

0 · Reply

Nganlm Oct. 8 at 4:12 PM

$ARCT huge volumes in Oct options today especially calls, some in Nov as well. For Oct, not sure if closing open positions or new ones. For Nov, should be new as open positions is low.

1 · Reply

SeeKingProphets Oct. 8 at 4:07 PM

$ARCT more manipulation today from the market maker. Paper hands need to move on. IYKYK 🌋

0 · Reply

bigchouse Oct. 8 at 4:07 PM

$ARCT Here are the MMs that are shorting. Woodline Partners LP Schonfeld Strategic Advisors LLC Balyasny Asset Management LP

0 · Reply

bigchouse Oct. 8 at 4:05 PM

$ARCT Short attack. I want to buy more cheaper.

0 · Reply

wahoowa96 Oct. 8 at 4:04 PM

$ARCT Make your move shorts....I am 🥱

0 · Reply

MaxCorona Oct. 8 at 4:00 PM

$ARCT hm, drops. Insiders?

1 · Reply

Choice79 Oct. 8 at 3:50 PM

$ARCT someone is selling hard and fast.

1 · Reply

judgeyoung2 Oct. 8 at 3:44 PM

$ARCT iv on the options just fell hard. i wonder if someone knows now that the data won’t be coming before 10/17.

0 · Reply

wahoowa96 Oct. 8 at 1:53 PM

$ARCT I think it can still find a bottom by going sideways around 20.5 till a dark clouds are cleared one way or another....Up and down it just feeds chipmunks.

0 · Reply

judgeyoung2 Oct. 8 at 1:29 PM

$ARCT they are going to give me a heart attack.

1 · Reply

wahoowa96 Oct. 8 at 1:02 PM

$ARCT I am staying with it...You don't get this many opportunities in the market to go from 14/share to 140/share...in two three years. It's better than BTC for me. ASTS announced 800M at the market shares selling for next two years and even a bank analyst gave underperform rating with 45 price tag. Share price was climbing to 74 from recent 50's...folks suggested it's an exit liquidity ramp as nd many sold at 72 73 and 75...It wasn't exit ramp. Verizon SD signed a commercial contract with ASTS. ARCT with so little resources are doing x100 times better works than big biopharma. Not many biopharma can tackle genetic rare diseases using mRNA like a breeze with so much purity along the way...

0 · Reply

QuantInsider Oct. 8 at 2:07 AM

$ARCT took a 2.6% hit today after yesterday's 11% jump Saw an aggressive play at 3:15 pm ET with 2,792 Oct 17 $30 calls swept at 325% IV, costing about $597K This move is all about short-dated upside into weakness With vol elevated and no other flow backing it up, this reads as tactical Need to see some confirmation like stabilization or higher lows before jumping in Keep it defined-risk only

0 · Reply

Zorrelak Oct. 7 at 10:49 PM

$ARCT data coming soon I would imagine in time for….. The North American Cystic Fibrosis Conference (NACFC) is the largest cystic fibrosis conference, and it is scheduled to take place virtually from October 23-25, 2025. This annual meeting gathers scientists, clinicians, and caregivers to share the latest in CF research, care, and drug development

0 · Reply

ma_sk Oct. 7 at 8:19 PM

$ARCT we cant know if they bought to close current positions or bougt to open new positions

1 · Reply

bigchouse Oct. 7 at 8:01 PM

$ARCT ARKG bought more shares. From 1,811,702 shares to 1,829,886 Increased shares by 18,184.

0 · Reply

Market Cap	570.53M
Revenue (ttm)	152.31M
Net Income (ttm)	-80.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-53.14%
Debt to Equity Ratio	0.00

Volume	626,605
Avg Vol	725,574
Day's Range	N/A - N/A
Shares Out	27.16M
Stochastic %K	45%
Beta	2.39
Analysts	Strong Sell
Price Target	$67.90